InSphero Acquires DOPPL SA and Sun Bioscience Gri3D Technology to Create Comprehensive 3D Cell Model Platform
核心洞察
InSphero AG (搜索) has signed a definitive agreement to acquire DOPPL SA (搜索) and Sun Bioscience (搜索)'s Gri3D® organoid culture platform technology to strengthen its position as a comprehensive provider of 3D in vitro models.
The acquisition combines InSphero's scalable spheroid technology with DOPPL's organoid assay expertise and Sun Bioscience (搜索)'s standardized microwell plate platform for uniform organoid formation.
The unified platform aims to accelerate pharmaceutical research by providing seamless access to both spheroids and organoids while replacing animal testing with human-relevant models for drug discovery and safety testing.
InSphero AG (搜索) has signed a definitive agreement to acquire DOPPL SA (搜索), including Sun Bioscience (搜索)'s Gri3D® technology, in a strategic move that positions the company as the most comprehensive provider of advanced 3D in vitro models for drug discovery and safety testing. The acquisition combines scalable spheroid and organoid technologies with integrated assay and data solutions to create a unified platform for pharmaceutical research.
Technology Integration Creates Comprehensive Platform
The acquisition brings together complementary technologies that address different aspects of 3D cell modeling. Sun Bioscience (搜索), founded in 2016, manufactures the Gri3D® organoid culture platform, an SBS-standard microwell plate technology that enables the formation of uniform organoids with high reproducibility and compatibility for automated handling and imaging. DOPPL SA (搜索) contributes deep expertise in organoid assay development, including epithelial barrier, oncology (搜索), and disease-specific organoid systems.
"With this acquisition, we unite the best of both worlds: the scalability and robustness of spheroids with the physiological depth of organoids," said Dr. Jan Lichtenberg, CEO and Co-Founder of InSphero. "Customers will benefit from a single, integrated partner who can deliver the right model for every research stage, from high-throughput safety testing to complex, patient-derived disease models, with consistent data quality and operational simplicity."
Unified Ecosystem for 3D Biology Research
The combined technologies form a powerful extension of InSphero's existing 3D InSight™ and Akura™ technology portfolio. The unified 3D model ecosystem offers customers seamless access to the full spectrum of 3D biology from standardized spheroids to complex organoids, all developed, produced, and quality-controlled under one roof.
The platform provides operational simplicity and reproducibility through one supplier providing assay-ready models, compatible plate formats, and harmonized workflows for automated imaging and screening. Additionally, the acquisition enables expanded biobanking for more diverse 3D in vitro models that capture patient-specific variations to better assess clinical outcomes.
Advancing Alternative Testing Methods
This strategic acquisition positions InSphero to better serve pharmaceutical, biotechnology, and academic customers seeking to replace animal testing with scalable, human-relevant models that deliver robust, predictive data for decision-making. The move addresses the growing demand for more physiologically relevant testing systems in drug development.
"Joining forces with InSphero marks the next chapter in our mission to make organoid technologies broadly accessible," said Jeroen Van den Oever, MBA, Co-Founder of DOPPL SA (搜索). "By combining our engineering and assay expertise with InSphero's industrial scale and global reach, we can deliver organoid solutions that are not only scientifically advanced but also practical for everyday use in pharmaceutical research."
Accelerating Organoid Technology Adoption
The integration creates what the companies describe as a unique end-to-end platform that combines Sun Bioscience (搜索)'s engineering of organoid culture systems and DOPPL's assay expertise with InSphero's industrial-scale 3D production and analytics capabilities.
"Combining Sun Bioscience (搜索)'s engineering of organoid culture systems and DOPPL's assay know-how with InSphero's industrial-scale 3D production and analytics creates a unique end-to-end platform," said Dr. Madhu Nag, Chief Scientific Officer of InSphero. "Together, we can accelerate the adoption of organoid technologies in drug discovery by making them as reliable and easy to use as established cell-based assays."